Literature DB >> 28870952

Metallothionein Isoform Expression in Benign and Malignant Thyroid Lesions.

Beata Wojtczak1, Bartosz Pula2, Agnieszka Gomulkiewicz2, Mateusz Olbromski2, Marzena Podhorska-Okolow2, Paweł Domoslawski3, Marek Bolanowski4, Jacek Daroszewski4, Piotr Dziegiel2,5.   

Abstract

BACKGROUND: Metallothioneins (MTs) are involved in numerous cell processes such as binding and transport of zinc and copper ions, differentiation, proliferation and apoptosis, therefore contributing to carcinogenesis. Scarce data exist on their expression in benign and malignant lesions of the thyroid.
MATERIALS AND METHODS: mRNA expression of functional isoforms of MT genes (MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1X, MT2A, MT4) was studied in 17 nodular goiters (NG), 12 follicular adenomas (FA) and 26 papillary thyroid carcinomas (PTC).
RESULTS: One-way ANOVA revealed significant differences in mRNA expression levels of MT1A (p<0.05), MT1E (p<0.005), MT1F (p<0.0001), MT1G (p<0.005), MT1X (p<0.0005) and MT2A (p<0.005) in the analyzed samples. Post hoc analysis confirmed a significantly lower expression of MT1A mRNA in PTC compared to NG (p<0.05). Significant down-regulation was also noted for other MT isoforms in PTC in comparison to NG: MT1E (p<0.05), MT1F (p<0.0001), MT1G (p<0.005), MT1X (p<0.0005) and MT2A (p<0.05). In addition, significant down-regulation of MT1F and MT1G in FA compared to NG was observed (p<0.005 and p<0.05, respectively).
CONCLUSION: Expression of functional MT isoforms may contribute to thyroid carcinogenesis and potentially serve as a diagnostic marker in distinguishing benign and malignant lesions. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Metallothioneins; papillary thyroid carcinoma; thyroid gland

Mesh:

Substances:

Year:  2017        PMID: 28870952     DOI: 10.21873/anticanres.11940

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  A case-control study of Metallothionein-1 expression in breast cancer and breast fibroadenoma.

Authors:  Fabiane Araújo Sampaio; Luana Mota Martins; Carla Solange de Melo Escorcio Dourado; Camila Maria Simplício Revoredo; Danylo Rafhael Costa-Silva; Victor Alves de Oliveira; Francisco Adelton Alves-Ribeiro; Benedito Borges da Silva
Journal:  Sci Rep       Date:  2019-05-15       Impact factor: 4.379

2.  Metallothionein-3 promotes cisplatin chemoresistance remodelling in neuroblastoma.

Authors:  Miguel Angel Merlos Rodrigo; Hana Michalkova; Vladislav Strmiska; Berta Casar; Piero Crespo; Vivian de Los Rios; J Ignacio Casal; Yazan Haddad; Roman Guran; Tomas Eckschlager; Petra Pokorna; Zbynek Heger; Vojtech Adam
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

3.  Construction of the Classification Model Using Key Genes Identified Between Benign and Malignant Thyroid Nodules From Comprehensive Transcriptomic Data.

Authors:  Qingxia Yang; Yaguo Gong
Journal:  Front Genet       Date:  2022-01-14       Impact factor: 4.599

4.  Effect of MT2A on apoptosis and proliferation in HL60 cells.

Authors:  Yu-Qing Pan; Min Niu; Shu-Min Liu; Yu-Xia Bao; Kai Yang; Xiao-Bo Ma; Liang He; Yi-Xun Li; Jie-Xian Cao; Xi Zhang; Yan Du
Journal:  Int J Med Sci       Date:  2021-06-04       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.